In a notable development on September 21, 2023, the Federal Trade Commission (FTC) filed a legal action in federal court against private equity firm, Welsh Carson, and its portfolio company, U.S. Anesthesia Partners (USAP). The FTC’s move represents its ongoing commitment to increase enforcement related to private equity companies and what are known as ‘roll-up’ acquisitions. Click here for more information.
For those unfamiliar, a ‘roll-up’ acquisition refers to a strategy through which a company acquires multiple smaller companies in the same market, often with the goal of consolidating market share. While this acquisition strategy offers potential benefits, such as increasing economies of scale, they can also attract regulatory scrutiny if they potentially limit competition.
Though private equity funds have managed to largely avoid direct scrutiny from regulators in the past, this case marks a potential shift in the FTC’s approach towards the industry, highlighting a more proactive regulatory stance. The repercussions of this lawsuit could have far-reaching implications for private equity funds and their portfolio companies with regard to transactional activity, particularly in the realm of roll-up acquisitions.
While it remains unclear as to how this case will ultimately unfold, legal professionals, especially those working in private equity, M&A and antitrust law, should monitor this situation carefully as it could significantly shape future regulation and enforcement in the PE space.